Document:

Exhibit
10.3

 

AMENDMENT
TO SHARE EXCHANGE AGREEMENT

 

THIS
AMENDMENT TO SHARE EXCHANGE AGREEMENT (the “Amendment”) is made effective as of September 15, 2016 by and among VIVOS
BIOTECHNOLOGIES, INC. (formerly, Corrective Biotechnologies, Inc.), a Wyoming corporation with offices located at 605 W. Know
Road, Suite 202, Tempe, Arizona 85284, (“Vivos Biotechnologies”), BIOMODELING SOLUTIONS, INC., an Oregon corporation
with offices located at 17933 NW Evergreen Pkwy., Suite 28, Beaverton, OR 97006 (“BioModeling”), the BioModeling shareholders
who have consented to this Amendment (the “BioModeling Shareholders”), FIRST VIVOS, INC., a Texas corporation with
offices at 514 Country Lane, Coppell, TX 75019 and the Vivos shareholders who have consented to this Amendment (the “Vivos
Shareholders”). Vivos Biotechnologies, BioModeling, the BioModeling Shareholders, Vivos and the Vivos Shareholders may collectively
be referred to as the “Parties”.

 

 BACKGROUND

 

A.
Vivos Biotechnologies, BioModeling, the BioModeling Shareholders, Vivos and the Vivos Shareholders are the parties to that certain
Share Exchange Agreement dated August 10, 2016 (the “Agreement”); and

 

B.
The Parties desire to amend certain parts of the Agreement as set forth below.

 

NOW,
THEREFORE, in consideration of the execution and delivery of the Agreement and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

 

1.
Section 5.01(A) of the Agreement is hereby deleted in its entirety and replaced with the following:

 

Section
5.01 (A) The Exchange. On the terms and subject to the conditions set forth in this Agreement, on the Closing Date
(as hereinafter defined): (i) the BioModeling Shareholders shall sell, assign, transfer and deliver to Vivos Biotechnologies,
free and clear of all liens, pledges, encumbrances, charges, restrictions or known claims of any kind, nature, or description,
not less than an aggregate of 80% of the shares of BioModeling held by the BioModeling Shareholders as a group; and (ii) the Vivos
Shareholders shall sell, assign, transfer and deliver to Vivos Biotechnologies, free and clear of all liens, pledges, encumbrances,
charges, restrictions or known claims of any kind, nature, or description, not less than an aggregate of 80% of the shares of
Vivos held by the BioModeling Shareholders as a group. The objective of such purchase (the “Exchange”) being the acquisition
by Vivos Biotechnologies of not less than an aggregate of 80% of the issued and outstanding shares of BioModeling and Vivos. In
exchange for the transfer of such common stock by the BioModeling Shareholders and the Vivos Shareholders, Vivos Biotechnologies
shall reserve and shall deliver to the BioModeling Shareholders and the Vivos Shareholders an aggregate of up to 20,000,000 shares
of Vivos Biotechnologies’ common stock in the amounts set forth on Exhibit A to this Agreement (the “Exchange Shares”)
and is hereinafter referred to as the “Exchange Consideration”. At the Closing Date, all share certificates of the
BioModeling Shareholders and the Vivos Shareholders who have agreed to exchange their shares for those of Vivos Biotechnologies
shall be cancelled and thereafter considered null and void and each shall, upon request, be entitled to receive a certificate
or certificates evidencing their ownership of the Exchange Shares. Currently Vivos Biotechnologies intends to maintain an electronic
record of shareholders and not issue paper certificates except upon request of a shareholder.

 

2.
Section 5.02 of the Agreement is hereby deleted in its entirety and replaced with the following:

 

Section
5.02 Closing. The closing (“Closing”) of the transactions contemplated by this Agreement shall occur following
completion of the conditions set forth in Articles VII and VIII, and upon delivery of the Exchange Consideration as described
in Section 5.01 herein. The Closing shall take place at a mutually agreeable time and place and is anticipated to close by no
later than September 30, 2016. The Board of Directors of Vivos Biotechnologies shall be authorized and empowered to accept, at
its sole and exclusive discretion, any late Exchange Consideration that may be presented to it after September 30, 2016.

 

3.
This Amendment shall be deemed part of, but shall take precedence over and supersede any provisions to the contrary contained
in the Agreement. All initial capitalized terms used in this Amendment shall have the same meaning as set forth in the Agreement
unless otherwise provided. Except as specifically modified hereby, all of the provisions of the Agreement which are not in conflict
with the terms of this Amendment shall remain in full force and effect.

 

    	 

     

    

 

SIGNATURE
PAGE FOR ENTITIES

 

IN
WITNESS WHEREOF, the corporate parties hereto have caused this Amendment to be executed by their respective officers, hereunto
duly authorized, as of the date first-above written.

 

	 	VIVOS
    BIOTECHNOLOGIES, INC.
	 	(formerly,
    Corrective Biotechnologies, Inc.)
	 	a
    Wyoming corporation
	 	 	 
	 	By:	 /s/
    Gregg C.E. Johnson 
	 	 	Gregg
    C. E. Johnson, Director & Secretary Treasurer

 

	 	BIOMODELING
    SOLUTIONS, INC.
	 	an
    Oregon corporation
	 	 
	 	By:	 /s/
    Dr. G. Dave Singh 
	 	 	Dr.
    Dave Singh, Chief Executive Officer

 

	 	FIRST
    VIVOS, INC. a Texas corporation
	 	 
	 	By:	 /s/
    R. Kirk Huntsman 
	 	 	R.
    Kirk Huntsman, Chief Executive Officer

 

    	- 2 -

     

    

 

EXHIBIT
A

 

EXCHANGE
SHARES FOR BIOMODELING SHAREHOLDERS

 

	Shareholder Name and Address	 	BioModeling Solutions
 Shares (to be exchanged) 
	 	 	Vivos
 Biotechnologies
 Shares* 
	 	 	% Interest in
 Vivos
 Biotechnologies after Exchange 
	 
	 	 	 	 	 	 	 	 	 	 
	Dr. Dave Singh	 	 	12,000,000	 	 	 	9,657,948	 	 	 	42.92	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dr. Martha Cortes	 	 	25,000	 	 	 	20,121	 	 	 	0.09	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Tara McLane Griffin	 	 	25,000	 	 	 	20,121	 	 	 	0.09	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Irma Jean Soderbery	 	 	200,000	 	 	 	160,966	 	 	 	0.72	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dennis Klemp and Melodi Klemp	 	 	50,000	 	 	 	40,241	 	 	 	0.18	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Charles S. Howard, Trustee of the C.S. Howard Trust u/a/d 11/4/03	 	 	25,000	 	 	 	20,121	 	 	 	0.09	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dr. Edna Santos	 	 	25,000	 	 	 	20,121	 	 	 	0.09	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mary Ann Baysac, DDS, MPH	 	 	25,000	 	 	 	20,121	 	 	 	0.09	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Thomas N. Toothacker	 	 	25,000	 	 	 	20,121	 	 	 	0.09	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Timothy A. Timmins	 	 	25,000	 	 	 	20,121	 	 	 	0.09	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total	 	 	12,425,000	 	 	 	10,000,000	 	 	 	44.44	%

 

*
Shares to be issued to shareholders of BioModeling who have consented to this Amendment.

 

    	- 3 -

     

    

 

EXCHANGE
SHARES FOR VIVOS SOLUTIONS SHAREHOLDERS

 

	Shareholder Name	 	Vivos Shares
 (to be exchanged) 
	 	 	Vivos
 Biotechnologies
 Shares* 
	 	 	% Interest in
 Vivos
 Biotechnologies after Exchange 
	 
	 	 	 	 	 	 	 	 	 	 
	R. Kirk Huntsman	 	 	2,800	 	 	 	5,600,000	 	 	 	24.89	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Joe Womack	 	 	550	 	 	 	1,100,000	 	 	 	4.89	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Susan McCullough	 	 	550	 	 	 	1,100,000	 	 	 	4.89	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	RaeAnn Byrnes	 	 	550	 	 	 	1,100,000	 	 	 	4.89	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Todd Huntsman	 	 	550	 	 	 	1,100,000	 	 	 	4.89	%
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total	 	 	5,000	 	 	 	10,000,000	 	 	 	44.44	%

 

*
Shares to be issued to shareholders of Vivos who have consented to this Amendment.

 

    	- 4 -Exhibit
10.4

 

INTELLECTUAL
PROPERTY & ASSET PURCHASE AGREEMENT

 

This
INTELLECTUAL PROPERTY & ASSET PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of the
4th day of May 2017 (the “Effective Date”) by and between VIVOS BIOTECHNOLOGIES, INC. (the “Buyer”),
a Wyoming corporation and Dr. Gurdev Dave Singh (the “Seller”).

 

R
E C I T A L S

 

WHEREAS,
the Seller desires to sell, transfer and assign to the Buyer and Buyer desires to purchase certain patents and other intellectual
property owned by the Seller (as hereinafter defined) in accordance with the terms and subject to the conditions set forth in
this Agreement.

 

NOW,
THEREFORE, in consideration of the promises and the mutual representations, warranties and covenants and subject to the conditions
contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the Buyer and Seller (each a “Party” and, collectively, the “Parties”), intending to be
legally bound, hereby agree as follows:

 

		1.	SALE
                                         OF ASSETS.

 

		1.1	Assets.
                                         The Seller hereby agrees to sell, assign and deliver to the Buyer at the Closing (as
                                         hereinafter defined), free and clear of all liens, pledges, options, claims, title defects,
                                         encumbrances, charges and other restrictions of every kind (collectively, the “Liens”)
                                         all right, title and interest in and to the intellectual property as hereafter described
                                         in this Section 1.1 (collectively, the “Assets”), including all Patents
                                         (as hereinafter defined), Marks (as hereinafter defined) and Other Property (as hereinafter
                                         defined)(collectively, the “Acquired Intellectual Property”). For
                                         greater certainty the Assets do not include Seller’s ownership of and copyright
                                         to written and copyrighted materials entitled Epigenetic Orthodontics.

 

		1.2	For
                                         purposes of this Agreement, the term “Patents” shall mean, collectively:

 

		1.2.1.	the
                                         patents and patent applications set forth in Schedule 1 and such patents and patent applications
                                         (wherever filed or contemplated to be filed) along with any supplemental or additional
                                         patent applications or registrations or divisionals, reissues, re-examination certificates,
                                         continuations, or provisional applications filed in the future by Seller that include
                                         the DNA Appliance System identified in such patents for any or all dental uses shall
                                         be collectively referred to as, the “Base Patents”;

 

    	-1-

     

    

 

		1.2.2.	all
                                         future improvements of the technology disclosed in the Base Patents, including, but not
                                         limited to, any additional patent applications that include the DNA Appliance System
                                         for all dental uses and supplemental or additional patent registrations or divisionals,
                                         reissues, re-examination certificates, continuations, or provisional applications filed
                                         in the future with respect to the Base Patents shall be collectively referred to as,
                                         the “Derivative Patents”; and

 

		1.2.3.	all
                                         future technology, patents and/or patent applications which include subject matter related
                                         to any and all dental appliances, and/or surgical instruments, apparatus and/or technics,
                                         as same may be subject to be protected by a patent in any country and shall be collectively
                                         referred to as, the “Other Patents”.

 

		1.3	For
                                         purposes of this Agreement, the term “Marks” shall mean, collectively
                                         all registered trademarks and service marks, and related applications for registration
                                         which are currently owned or used by Seller in connection with the Products (as hereinafter
                                         defined) and the Patents including the names “DNA” and “mRNA”.

 

		1.4	For
                                         purposes of this Agreement, the term “Products” shall mean, the DNA
                                         appliances and any other products based on the technology included in the Patents, Base
                                         Patents, the Other Patents or the Derivative Patents or use the Marks.

 

		1.5	For
                                         purposes of this Agreement, the term “Other Property” shall also include,
                                         for clarity, but without operating as any limitation: all business plans, business models,
                                         products, product plans, product concepts, designs, drawings, specifications, engineering
                                         information, processes, applications, research, test data, technology, software, source
                                         code, trade secrets, formulas, algorithms, hardware configuration information, know-how,
                                         ideas, inventions, improvements, innovations, financial analysis, forecasts, market information,
                                         marketing plans, customer data, customer lists, customer names, lists of prospects, leads,
                                         accounts, clients, and relationships, vendor names and related information, pricing information,
                                         agreements, disclosure documents, memoranda, reports, summaries, overviews, forecasts,
                                         brochures, analyses, compilations, studies or any other information or Documents compiled
                                         or prepared by the Seller, the Seller’s predecessor company BMS Solutions, Inc.
                                         or its or his Affiliates at any time prior to the date hereof.

 

		1.5.1.	“Documents”
                                         means any and all printed, typewritten, handwritten, recorded or computerized information,
                                         including, without limitation, text diagrammatic, photographic, video, virtual reality,
                                         web-based, coded, multimedia, and graphic material, or other tangible representation
                                         or mode of expression of any kind, suitable for the manifestation, storage, or communication
                                         of any idea, data, abstract, relation, interpretation, though, expression of imagination,
                                         or other information.

 

    	-2-

     

    

 

		1.5.2.	“Affiliates”
                                         means (i) any officer, director, trustee, general partner, employee or holder of ten
                                         percent (10%) or more of any class of the voting securities of, or equity interest in,
                                         such party; (ii) any corporation, partnership, or other entity controlling, controlled
                                         by, or under common control with such party; (iii) any officer, director, trustee, general
                                         partner, employee or holder of ten percent (10%) or more of any class of the voting securities
                                         of, or equity interest in, any corporation, partnership, or other entity controlling,
                                         controlled by, or under common control with such party; and (d) any relative or spouse,
                                         or any relative of such spouse of the party.

 

		1.6	The
                                         parties acknowledge and agree that Buyer shall not assume any of Seller’s liabilities
                                         or obligations related to the Assets or otherwise, whether accrued, absolute, contingent
                                         or otherwise including, without limitation, any liability or obligation with respect
                                         to: (i) any claim for injury to persons or property; (ii) any employees, agents, independent
                                         contractors or creditors of the Seller or under any plan or arrangement with respect
                                         thereto and for wages, salaries, bonuses, commissions, sick pay, vacation or holiday
                                         pay, overtime or other benefits; (iii) any tax, assessment or other governmental imposition
                                         of any type or description, including, without limitation, any income or excess profits
                                         taxes or local income, sales, use, excise, value added, ad valorem or franchise taxes,
                                         together with any interest, assessments and penalties thereon; (iv) any violation by
                                         the Seller of any requirement of law prior to the Closing Date; (v) any litigation or
                                         other legal proceedings, claims or investigations related to the Seller or the Assets.

 

		2.	PURCHASE
                                         PRICE.

 

		2.1	Purchase
                                         Price. The Assets shall be sold by the Seller and shall be purchased by the Buyer
                                         for an aggregate purchase price of Five Million Dollars ($5,000,000.00) (the “Purchase
                                         Price”). The Purchase Price shall be satisfied by the delivery to the Seller
                                         of One Million (1,000,000) shares of the Buyer’s Series A Convertible Preferred
                                         Stock subject to the Security Agreement attached hereto as Exhibit A. A form of
                                         the Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred
                                         Stock (the “Series A Preferred”) is attached hereto as Exhibit
                                         B. The Series A Preferred shall be issued to the Seller at Closing.

 

		2.2	Expenses
                                         in connection with the assignment and delivery of the Assets shall be paid by the
                                         Buyer.

 

		3.	CLOSING.
                                         The closing (the “Closing” or “Closing Date”)
                                         of the transactions contemplated by this Agreement shall take place on May 4th,
                                         2017 at such place designated by Buyer. At the Closing, the Buyer and the Seller shall
                                         deliver evidence reasonably satisfactory to the other party that each of the conditions
                                         to the obligations of such party set forth in Section 4 of this Agreement has been satisfied
                                         and resolutions of their respective boards of directors (and shareholders if necessary
                                         according to local law) approving the transaction. The Seller shall deliver a bill of
                                         sale or other documents evidencing transfer of legal title, if required, to the Assets
                                         and the Buyer shall deliver the Series A Preferred as set forth in Section 2.1 of this
                                         Agreement.

 

    	-3-

     

    

 

		4.	REPRESENTATIONS
                                         AND WARRANTIES OF SELLER. In order to induce the Buyer to enter into this Agreement
                                         and to consummate the transactions contemplated under this Agreement, the Seller makes
                                         the following representations, warranties and covenants, each of which is relied upon
                                         by Buyer in consummating the transactions contemplated hereby regardless of any other
                                         investigation made or information obtained by the Buyer:

 

		4.1	Good
                                         Title to and Condition of the Assets. The Seller has good and marketable title to
                                         the Assets, free and clear of all Liens. There are no unpaid taxes or other matters which
                                         are or could become a Lien on the Assets.

 

		4.2	Acquired
                                         Intellectual Property. 

 

		4.2.1.	BMS
                                         Solutions previous sold and transferred all its Marks to the Purchaser. Save and except
                                         for those Marks previously sold by BMS Solutions, Inc., the Seller exclusively owns all
                                         rights in the Patents and the Other Assets, free and clear of all license agreements,
                                         distribution agreements, restrictions on further licensing, obligations to make payments
                                         to third parties, or security interests, mortgages or liens. No entity or person other
                                         than the Seller has any rights granted by Seller (either current or contingent) to use,
                                         make, sell or practice, the inventions protected by any Patents, no person or entity
                                         retains any right to use, make, sell or practice any invention protected by a Patent,
                                         and no person or entity retains any such rights. Except for office actions issued by
                                         the U.S. Patent and Trademark Office or a similar office or agency anywhere in the world,
                                         the Seller has not received any communications alleging that any Patents are invalid
                                         or unenforceable, and Seller has no knowledge of any basis to allege that any Patents
                                         are invalid or unenforceable.

 

		4.2.2.	All
                                         Patents which are issued or pending before, as applicable, the U.S. Patent and Trademark
                                         Office, are currently in compliance with formalities and legal requirements necessary
                                         to maintain them as currently valid (including without limitation as applicable, the
                                         payment of all necessary fees, including without limitation, filing, examination, annuity,
                                         maintenance or other fees, and the filing of all necessary documents or statements, including
                                         without limitation, necessary proofs of working or use, or other items or documents necessary
                                         to maintain such Patents as currently valid).

 

		4.2.3.	Seller
                                         has not licensed the Patents, Marks or Other Assets from any other person or entity save
                                         and except for the licenses that make up the BMS licenses.

 

    	-4-

     

    

 

		4.2.4.	To
                                         the knowledge of Seller, no entity has or is infringing upon any Patents or any other
                                         Seller proprietary rights.

 

		4.3	Compliance
                                         With Laws; Litigation. There exist no violations of local laws or orders of any governmental
                                         authority in respect of the Assets, which could result in an effect reasonably likely
                                         to affect the Seller or the Assets, to the extent of US$10,000 for any single item. There
                                         exist no actions, suits, claims, proceedings or inquiries of a governmental authority
                                         pending or threatened relating to the Assets.

 

		4.4	Litigation
                                         and Proceedings. There are no actions, suits, proceedings, or investigations pending
                                         or, to the knowledge of Seller after reasonable investigation, threatened by or against
                                         Seller or affecting the Assets, at law or in equity, before any court or other governmental
                                         agency or instrumentality, domestic or foreign, or before any arbitrator of any kind.
                                         Seller does not have any knowledge of any default on their part with respect to any judgment,
                                         order, injunction, decree, award, rule, or regulation of any court, arbitrator, or governmental
                                         agency or instrumentality or of any circumstances which, after reasonable investigation,
                                         would result in the discovery of such a default.

 

		4.5	Investment
                                         Representations. Seller understands that the Series A Preferred have not been registered
                                         under the Securities Act of 1933, as amended (the “Securities Act”)
                                         and that the Series A Preferred are being offered and sold pursuant to an exemption from
                                         registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D
                                         promulgated thereunder based in part upon Seller’s representations contained in
                                         the Agreement.

 

		4.5.1.	Information
                                         on Seller. The Seller (i) is, and will be on the date of the Closing Date, an “Accredited
                                         Investor”, as such term is defined in Regulation D promulgated by the Securities
                                         and Exchange Commission under the Securities Act, (ii) is experienced in investments
                                         and business matters, (iii) has made investments of a speculative nature and has purchased
                                         securities of United States publicly-owned companies in private placements in the past
                                         and, (iv) alone or with its representatives, has such knowledge and experience in financial,
                                         tax and other business matters as to enable the Seller to utilize the information made
                                         available by Buyer to evaluate the merits and risks of and to make an informed investment
                                         decision with respect to the sale of the Seller’s assets to the Buyer in exchange
                                         for the Series A Preferred and other consideration set forth in this Agreement, which
                                         Series A Preferred represent a speculative investment. The Seller is able to bear the
                                         risk of such investment for an indefinite period and to afford a complete loss thereof.

 

		4.5.2.	Acquisition
                                         of Series A Preferred. On the Closing Date, the Seller will acquire the Series A
                                         Preferred as principal for its own account for investment only and not with a view toward,
                                         or for resale in connection with, the public sale or any distribution thereof, and Seller
                                         has not agreed to hold the Series A Preferred for any minimum amount of time.

 

    	-5-

     

    

 

		4.5.3.	Compliance
                                         with Securities Act. The Seller understands and agree that the Series A Preferred
                                         have not been registered under the 1933 Act or any applicable state securities laws,
                                         by reason of their issuance in a transaction that does not require registration under
                                         the Securities Act (based in part on the accuracy of the representations and warranties
                                         of Seller contained herein), and that such Series A Preferred must be held indefinitely
                                         unless a subsequent disposition is registered under the Securities Act or any applicable
                                         state securities laws or is exempt from such registration.

 

		4.5.4.	Legends
                                         on Series A Preferred. The Series A Preferred shall bear the following or similar
                                         legend:

 

“THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THESE SHARES MAY
NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH SECURITIES
ACT AND ANY APPLICABLE STATE SECURITIES LAW OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO VIVOS BIOTECHNOLOGIES, INC. THAT
SUCH REGISTRATION IS NOT REQUIRED.”

 

		4.5.5.	Communication
                                         of Offer. The offer to purchase the Assets in exchange for the Series A Preferred
                                         and other consideration set forth in this Agreement was directly communicated to the
                                         Seller by Buyer. At no time was the Seller presented with or solicited by any leaflet,
                                         newspaper or magazine article, radio or television advertisement, or any other form of
                                         general advertising or solicited or invited to attend a promotional meeting otherwise
                                         than in connection and concurrently with such communicated offer.

 

		4.6	Information.
                                         The information concerning Seller set forth in this Agreement and the schedules is complete
                                         and accurate in all material respects and does not contain any untrue statements of a
                                         material fact or omit to state a material fact required to make the statements made,
                                         in light of the circumstances under which they were made, not misleading. In addition,
                                         Seller have fully disclosed in writing to Buyer (through this Agreement or the schedules)
                                         all information relating to matters involving Seller or the Assets which (i) indicated
                                         or may indicate, in the aggregate, the existence of a greater than $10,000 liability
                                         , (ii) have led or may lead to a competitive disadvantage on the part of Seller or (iii)
                                         either alone or in aggregation with other information covered by this Section, otherwise
                                         have led or may lead to a material adverse effect on Seller, its assets, or its operations
                                         or activities as presently conducted or as contemplated to be conducted after the Closing
                                         Date, including, but not limited to, information relating to governmental, employee,
                                         environmental, litigation and securities matters and transactions with affiliates.

 

    	-6-

     

    

 

		5.	REPRESENTATIONS
                                         AND WARRANTIES OF BUYER. The Buyer represents and warrants that:

 

		5.1	Corporate
                                         Authority. The Buyer is a corporation duly organized, validly existing and in good
                                         standing under the laws of Wyoming and has full corporate power and authority to perform
                                         the transactions and agreements contemplated by this Agreement.

 

		5.2	Authorization;
                                         Binding Obligation: Consents. The execution, delivery and performance of this Agreement
                                         have been authorized by all necessary corporate, shareholder and legal action on the
                                         part of the Buyer. This Agreement has been duly executed and delivered by the Seller
                                         and is the legal, valid and binding obligation of the Seller enforceable against it in
                                         accordance with its terms.

 

		6.	CONDITIONS
                                         TO THE OBLIGATIONS OF THE BUYER. The obligation of the Buyer to consummate the
                                         transactions contemplated by this Agreement shall be subject to the fulfillment at or
                                         prior to the Closing of each of the following conditions:

 

		6.1	Accuracy
                                         of Representations and Warranties and Compliance with Obligations. The representations
                                         and warranties of the Seller in this Agreement shall be true and correct in all material
                                         respects on the date of this Agreement and on the Closing Date. The Seller shall have
                                         performed and complied with all of its obligations required by this Agreement to be performed
                                         or complied with at or prior to the Closing and shall have delivered to the Buyer copies
                                         of resolutions adopted by the board of directors and, if necessary, shareholders of the
                                         Seller authorizing the transactions contemplated by this Agreement, as well as any consents
                                         required to consummate such transactions and completed its undertaking set forth in Section
                                         6.

 

		6.2	No
                                         Adverse Action. There shall not be pending or threatened any action before any court
                                         or other governmental authority which shall seek to prohibit or invalidate the delivery
                                         of the Assets to the Buyer, or which might adversely affect the right of the Buyer to
                                         utilize the Assets. The Assets shall not have been materially affected by any event or
                                         circumstance after the date of this Agreement.

 

		7.	CONDITIONS
                                         TO THE OBLIGATIONS OF THE SELLER. The obligation of the Seller to consummate
                                         the transactions contemplated by this Agreement shall be subject to the fulfillment at
                                         or prior to the Closing Date of each of the following conditions:

 

    	-7-

     

    

 

		7.1	Accuracy
                                         of Representations and Warranties and Compliance with Obligations. The representations
                                         and warranties of the Buyer in this Agreement shall be true and correct in all material
                                         respects on the date of this Agreement and on the Closing Date. The Buyer shall have
                                         performed and complied with all of its obligations required by this Agreement to be performed
                                         or complied with at or prior to the Closing and shall have delivered to the Seller copies
                                         of resolutions adopted by the board of directors of the Seller authorizing the transactions
                                         contemplated by this Agreement.

 

		7.2	Employment
                                         Agreement. Prior to the Closing, the Buyer shall enter into an employment agreement
                                         with the Seller, on or before the Closing date, on such terms and conditions as mutually
                                         agreed to by the parties (the “Employment Agreement”).

 

		8.	CERTAIN
                                         ACTIONS AFTER THE CLOSING.

 

		8.1	Further
                                         Assurances. After the Closing, upon the reasonable request of the other, each Party
                                         shall execute and deliver all further documents and instruments and shall take such other
                                         steps as may be reasonably necessary to effectuate the transactions contemplated hereby.
                                         In addition, each Party shall cooperate with and provide information, records, documents
                                         and assistance with respect to claims or liabilities that may arise after the Closing.

 

		9.	INDEMNIFICATION.

 

		9.1	Indemnity
                                         by the Seller. The Seller agrees to indemnify and hold the Buyer and its officers,
                                         directors, employees and agents and (collectively, the “Buyer Indemnitees”)
                                         harmless from all Buyer Indemnified Liabilities. For this purpose, “Buyer Indemnified
                                         Liabilities” shall mean all suits, proceedings, claims, expenses, losses, costs,
                                         liabilities, judgments, deficiencies, assessments, actions, investigations, penalties,
                                         fines, settlements, interest and damages (including reasonable attorneys’ fees
                                         and expenses), whether suit is instituted or not and, if instituted, whether at any trial
                                         or appellate level, and whether raised by the parties hereto or a third party, incurred
                                         or suffered by the Buyer Indemnitees or any of them arising from, in connection with
                                         or as a result of (a) any false or inaccurate representation or warranty made by or on
                                         behalf of the Seller in or pursuant to this Agreement; (b) any default or breach in the
                                         performance of any of the covenants or agreements made by the Seller in or pursuant to
                                         this Agreement; (c) that any Patents or Marks infringes upon any patent, or any copyright,
                                         trademark, or trade secret of any third party; and (d) any obligation or liability of
                                         the Seller which Buyer has not assumed.

 

		9.2	Indemnity
                                         by the Buyer. The Buyer agrees that it will indemnify and hold the Seller and its
                                         officers, directors, employees and agents harmless (collectively, the “Seller
                                         Indemnitees”) from all Seller Indemnified Liabilities. For this purpose, “Seller
                                         Indemnified Liabilities” incurred by the Seller means all suits, proceedings,
                                         claims, expenses, losses, costs, liabilities, judgments, deficiencies, assessments, actions,
                                         investigations, penalties, fines, settlements, interest and damages (including reasonable
                                         attorneys’ fees and expenses), whether suit is instituted or not and, if instituted,
                                         whether at any trial or appellate level, and whether raised by the parties hereto or
                                         a third party, incurred or suffered by the Seller, arising from, in connection with or
                                         as a result of (a) any false or inaccurate representation or warranty made by or on behalf
                                         of the Buyer in or pursuant to this Agreement; (b) any default or breach in the performance
                                         of any of the covenants or agreements made by the Buyer in this Agreement; or (c) the
                                         use of the Assets after the Closing Date.

 

    	-8-

     

    

 

		9.3	Procedure
                                         for Indemnification.

 

		9.3.1.	In
                                         the event any person or entity not a party to this Agreement shall make any demand or
                                         claim or file or threaten to file or continue any lawsuit, which demand, claim or lawsuit
                                         may result in Buyer Indemnified Liabilities or Seller Indemnified Liabilities, as the
                                         case may be, the indemnified party shall give written notice to such effect to the indemnifying
                                         party promptly upon becoming aware thereof. In such event, the indemnifying party shall
                                         assume full control of the defense thereof and hire counsel (which counsel shall be reasonably
                                         satisfactory to the indemnified party) to defend any such demand, claim or lawsuit (provided,
                                         however, that the failure to give such Notice shall not relieve the indemnifying party
                                         of its obligations hereunder). The indemnified party shall be permitted to participate
                                         in such defense at its sole cost and expense, provided that if the indemnifying party
                                         proposes that the same counsel represent both the indemnified party and the indemnifying
                                         party and representation of both parties by the same counsel would be inappropriate due
                                         to actual or potential differing interests between them, then the indemnified party shall
                                         have the right to retain its own counsel at the cost and expense of the indemnifying
                                         party. In the event that the indemnifying party shall fail to respond within twenty (20)
                                         days after receipt of the notice from the indemnified party of any such demand, claim
                                         or lawsuit, then the indemnified party may retain counsel and conduct the defense of
                                         such demand, claim or lawsuit, as it may in its sole discretion deem proper, at the sole
                                         cost and expense of the indemnifying party.

 

		9.3.2.	With
                                         regard to claims of third parties for which indemnification is payable hereunder, such
                                         indemnification shall be paid in advance of settlement or final adjudication thereof
                                         on a current basis within 30 days of receipt from the indemnified party of such supporting
                                         documentation as the indemnifying party may reasonably request. To the extent that the
                                         Seller fails to indemnify the Buyer for any Buyer Indemnified Liabilities, the Buyer
                                         shall have the right to set off the Buyer Indemnified Liabilities against the Series
                                         A Preferred.

 

    	-9-

     

    

 

		10.	TERMINATION.

 

		10.1	Termination.
                                         This Agreement may be terminated and the transactions contemplated hereby may be abandoned,
                                         but not later than the Closing Date:

 

		10.1.1.	by
                                         mutual written consent of the Buyer and the Seller;

 

		10.1.2.	by
                                         the Buyer, in its sole discretion, if any of the representations or warranties of the
                                         Seller contained herein are not in all material respects true, accurate and complete
                                         or if the Seller breaches or fails to comply with any covenant or agreement contained
                                         herein; or

 

		10.1.3.	by
                                         the Seller, in its sole discretion, if any of the representations or warranties of the
                                         Buyer contained herein are not in all material respects true, accurate and complete or
                                         if the Buyer breaches or fails comply with any covenant or agreement contained herein.

 

		10.2	Effect
                                         of Termination. In the event of a termination of this Agreement pursuant to Section
                                         11.1, written notice thereof shall promptly be given to the other party hereto and this
                                         Agreement shall terminate and the transactions contemplated hereby shall be abandoned
                                         without further action by the other party hereto. Notwithstanding such termination, each
                                         party shall have the right to seek damages in the event of a breach by the other party
                                         of its obligations under this Agreement.

 

		11.	MISCELLANEOUS.

 

		11.1	Amendment
                                         and Modification; Assignment; Binding Effect. This Agreement may only be amended
                                         by written instrument signed by the parties hereto. No party shall assign its rights
                                         or delegate its duties hereunder without the prior written consent of the other party.
                                         This Agreement shall be binding upon and inure to the benefit of the parties and their
                                         respective successors and permitted assigns.

 

		11.2	Entire
                                         Agreement. This Agreement and the schedules and exhibits attached hereto constitute
                                         the entire agreement of the parties with respect to the sale of the Assets and the other
                                         transactions contemplated in this Agreement, and supersede all prior understandings,
                                         agreements and oral representations and warranties of the parties with respect to the
                                         subject matter of this Agreement.

 

		11.3	Execution
                                         in Counterparts, Electronic Transmission. This Agreement may be executed in any number
                                         of counterparts, each of which shall be deemed an original. The signature of any party
                                         to this Agreement which is transmitted by any reliable electronic means such as, but
                                         not limited to, a photocopy, electronically scanned or facsimile machine, for purposes
                                         hereof, is to be considered as an original signature, and the document transmitted is
                                         to be considered to have the same binding effect as an original signature or an original
                                         document.

 

    	-10-

     

    

 

		11.4	Headings.
                                         The section headings contained in this Agreement are inserted for convenience only and
                                         shall not affect in any way the meaning or interpretation of this Agreement.

 

		11.5	Notices.
                                         Any notice, request, information or other document to be given hereunder to any of the
                                         parties by any other party shall be in writing and shall be either hand delivered, delivered
                                         by facsimile, electronic mail, mailed by overnight delivery service or by registered
                                         or certified mail (postage prepaid), return receipt requested, addressed to:

 

As
to the Buyer:

 

Vivos
BioTechnologies, Inc.

605
W. Knox Rd.

Suite
102

Tempe,
AZ 85284

 

As
to the Seller

 

Dr.
Gurdev Dave Singh

5425
SE Clearbrook St.

Hillsboro,
OR 97123

 

Any
such notice shall be deemed delivered (a) on the date delivered if by personal delivery or by facsimile or email, or (b) on the
date upon which the return receipt is signed or delivery is refused or not deliverable, as the case may be, if mailed. Any party
may change the address to which notices under this Agreement are to be sent to it by giving written notice thereof.

 

		11.6	Governing
                                         Law. This Agreement will be governed in all respects by the internal laws of the
                                         State of Colorado (without giving effect to the conflicts of law principles thereof).

 

		11.7	Service
                                         of Process; Jurisdiction; Waiver of Jury Trial Rights.

 

		11.7.1.	Each
                                         of the parties hereto irrevocably consents to the service of any process, pleading, notices
                                         or other papers by the mailing of copies thereof by any means permitted pursuant to Section
                                         12.4 above or by any other method provided or permitted under Colorado law.

 

		11.7.2.	Each
                                         party hereby irrevocably and unconditionally submits to the exclusive jurisdiction of
                                         any state or federal court sitting in Colorado over any suit, action or proceeding arising
                                         out of or relating to this Agreement. Each party hereby irrevocably and unconditionally
                                         waives any objection to the laying of venue of any such suit, action or proceeding brought
                                         in any such court and any claim that any such suit, action or proceeding brought in any
                                         such court has been brought in an inconvenient forum. Each party hereby agrees that a
                                         final judgment in any such suit, action or proceeding brought in any such court shall
                                         be conclusive and binding upon such party and may be enforced in any other courts to
                                         whose jurisdiction such party is or may be subject, by suit upon such judgment.

 

    	-11-

     

    

 

		11.7.3.	Each
                                         party hereto specifically waives any right it might otherwise have to a jury trial with
                                         respect to any matter arising under this Agreement.

 

		11.8	Attorneys’
                                         Fees. If any party to this Agreement brings an action to enforce its rights arising
                                         out of or relating to this Agreement, the prevailing party shall be entitled to recover
                                         its costs and expenses, including without limitation reasonable attorneys’ fees,
                                         incurred in connection with such action, including any appeal of such action.

 

		11.9	Severability.
                                         If any court, arbitrator or administrative agency of a competent jurisdiction finds any
                                         provision of this Agreement is illegal, invalid or unenforceable but would be legal,
                                         valid or enforceable if some part or parts of it were deleted or modified, or if the
                                         period or area of application were reduced, then such provision shall apply automatically
                                         with such modification as is necessary to make it legal, valid and enforceable under
                                         applicable laws, and otherwise this Agreement shall continue in full force and effect.

 

		11.10	Amendment;
                                         Waiver. This Agreement shall not be amended except in an instrument in writing signed
                                         on behalf of each of the parties hereto. No waiver of this Agreement shall be binding
                                         unless executed in writing by the party to be bound thereby. No waiver of any of the
                                         provisions of this Agreement shall be deemed or shall constitute a waiver of any other
                                         provision hereof (whether or not similar), nor shall such waiver constitute a continuing
                                         waiver unless otherwise expressly provided.

 

		11.11	Injunctive
                                         Relief. Each party acknowledges and agrees that a breach by either party of any of
                                         the covenants or agreements contained herein will result in irreparable and continuing
                                         damage to the other party for which there will be no adequate remedy at law. Accordingly,
                                         each party hereto agrees that such other party shall be entitled to injunctive relief
                                         and/or a decree for specific performance, (without need to post a bond or other security),
                                         in addition to all such other relief as may be proper (including monetary damages if
                                         appropriate) at law or in equity.

 

		11.12	Counterparts.
                                         This Agreement may be executed in one or more counterparts, any of which may be executed
                                         and transmitted by facsimile or other electronic means, and each of which shall be deemed
                                         an original, but all of which together shall constitute one and the same instrument.
                                         The exchange of signed counterparts by each of the parties, including exchange by electronic
                                         means, will constitute effective execution and delivery of this Agreement.

 

    	-12-

     

    

 

		11.13	Interpretation.
                                         Each party hereto has reviewed, and has had an adequate opportunity to have its attorney
                                         review, this Agreement. Any controversy over construction of this Agreement shall be
                                         decided without regard to events of authorship or negotiation.

 

		11.14	Expenses.
                                         Except as otherwise provided in this Agreement, all legal, accounting and other costs
                                         and expenses incurred in connection with this Agreement and transactions contemplated
                                         by this Agreement shall be paid by the Buyer.

 

		11.15	Waiver.
                                         Any party to this Agreement may extend the time for or waive the performance of any of
                                         the obligations of the other, waive any inaccuracies in the representations or warranties
                                         by the other, or waive compliance by the other with any of the covenants or conditions
                                         contained in this Agreement. Any such extension or waiver shall be in writing and signed
                                         by an officer of the waiving party. No such waiver shall operate or be construed as a
                                         waiver of any subsequent act or omission of the parties.

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

 

	Buyer:	VIVOS
    BIOTECHNOLOGIES, INC.	 
	 	 	 
	 	 /s/
    R. Kirk Huntsman 	 
	 	R.
    Kirk Huntsman, Chief Executive Officer	 
	 	 	 
	Seller:	DR.
    GURDEV DAVE SINGH	 
	 	 	 
	 	 /s/
    Dr. G. Dave Singh 	 
	 	Dr.
    Gurdev Dave Singh	 

 

    	-13-

     

    

 

EXHIBIT
A

 

SECURITY
AGREEMENT

 

    	-14-

     

    

 

EXHIBIT
B

 

CERTIFICATE
OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A PREFERRED STOCK

 

    	-15-

     

    

 

SCHEDULE
1

 

PATENTS

 

US
7,887,324 B2: Osteogenetic-Orthodontic Device, System, and Method

US
8,192,196 B2: Osteogenetic-Pneumopedic Appliance, System and Method

US
D600,350 S: Orthodontic Spring

US
D636,083 S: Spring

US
D704,843 S: Sleep Appliance

US
D713,530 S: Sleep Appliance

US
D731,659 S: Sleep Appliance

US
D736,945 S: Sleep Appliance

 

CA
2 675 496 C: Osteogenetic-Orthodontic Device, System, and Method

CA
2 688 688 C: Osteogenetic-Pneumopedic Appliance, System and Method

 

    	-16-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]